Severe food allergy and anaphylaxis : treatment, risk assessment and risk reduction

Show simple item record

dc.contributor.author Risenga, Samuel Malamulele
dc.contributor.author Kriel, M.
dc.contributor.author Karabus, S.
dc.contributor.author Manjra, Ahmed I.
dc.contributor.author Gray, Claudia L.
dc.contributor.author Goddard, E.
dc.contributor.author Lang, A.C.
dc.contributor.author Terblanche, Alta J.
dc.contributor.author Van der Spuy, D.A.
dc.contributor.author Levin, M.E.
dc.date.accessioned 2015-03-03T05:59:42Z
dc.date.available 2015-03-03T05:59:42Z
dc.date.issued 2015-01
dc.description.abstract An anaphylactic reaction may be fatal if not recognised and managed appropriately with rapid treatment. Key steps in the management of anaphylaxis include eliminating additional exposure to the allergen, basic life-support measures and prompt intramuscular administration of adrenaline 0.01 mg/kg (maximum 0.5 mL). Adjunctive measures include nebulised bronchodilators for lower-airway obstruction, nebulised adrenaline for stridor, antihistamines and corticosteroids. Patients with an anaphylactic reaction should be admitted to a medical facility so that possible biphasic reactions may be observed and risk-reduction strategies initiated or reviewed after recovery from the acute episode. Factors associated with increased risk of severe reactions include co-existing asthma (and poor asthma control), previous severe reactions, delayed administration of adrenaline, adolescents and young adults, reaction to trace amounts of foods, use of non-selective β-blockers and patients who live far from medical care. Risk-reduction measures include providing education with regard to food allergy and a written emergency treatment plan on allergen avoidance, early symptom recognition and appropriate emergency treatment. Risk assessment allows stratification with provision of injectable adrenaline (preferably via an auto-injector) if necessary. Patients with ambulatory adrenaline should be provided with written instructions regarding the indications for and method of administration of this drug and trained in its administration. Patients and their caregivers should be instructed about how to avoid foods to which the former are allergic and provided with alternatives. Permission must be given to inform all relevant caregivers of the diagnosis of food allergy. The patient must always wear a MedicAlert necklace or bracelet and be encouraged to join an appropriate patient support organisation. en_ZA
dc.description.librarian hb2015 en_ZA
dc.description.uri http://www.samj.org.za en_ZA
dc.identifier.citation Risenga, SM, Kriel, M, Karabus, S, Manjra, AI, Gray, CL, Goddard, E, Lang, AC, Terblanche, AJ, Van der Spuy, DA & Levin, ME 2015, 'Severe food allergy and anaphylaxis : treatment, risk assessment and risk reduction', South African Medical Journal , vol. 105, no. 1, pp. 72-73. en_ZA
dc.identifier.issn 0256-9574 (print)
dc.identifier.issn 2078-5135 (online)
dc.identifier.issn 10.7196/SAMJ.9099
dc.identifier.uri http://hdl.handle.net/2263/43838
dc.language.iso en en_ZA
dc.publisher Health and Medical Publishing Group en_ZA
dc.rights © 2015 Health & Medical Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0). en_ZA
dc.subject Severe food allergy en_ZA
dc.subject Anaphylaxis en_ZA
dc.subject Treatment en_ZA
dc.subject Risk assessment en_ZA
dc.subject Risk reduction en_ZA
dc.subject Allergic reactions to foods en_ZA
dc.title Severe food allergy and anaphylaxis : treatment, risk assessment and risk reduction en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record